Palvella Therapeutics, Inc. PVLA

138.16 (7.91) (5.42%) as of 25 Sep
Market cap
$2.1B
P/E
0.0×
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
29.36 72.63 128.11 104.15 70.44 117.76 59.17 7.35 83.60 57.98
Receivables
0.06 15.55 2.70 6.79 1.71 3.31 11.04 6.04 2.34 —
Total current assets
32.67 89.79 135.38 115.01 75.72 127.63 73.42 7.55 88.23 58.99
Property, Plant, Equpment (Net)
2.26 4.03 5.05 19.50 22.05 19.12 16.99 — — —
Long-Term Investments
— 9.92 — — — — — — — —
Long-term assets (Other)
0.13 0.13 0.91 3.15 3.31 2.90 1.37 — — —
Total non-current assets
2.39 14.09 5.96 26.08 29.29 25.94 22.07 — — 0.57
Total Assets
35.06 103.88 141.34 141.10 105.01 153.56 95.49 7.55 88.23 59.56
Accounts Payable
2.39 2.45 3.35 5.80 1.79 8.61 4.15 0.94 4.59 4.60
Accrued Expenses
— 6.17 9.11 9.94 7.73 16.84 10.75 1.42 5.47 4.35
Current Revenue (Deferred)
2.28 37.15 35.61 11.26 12.63 25.12 20.82 — — —
Other current liabilities
3.72 43.32 44.73 20.47 19.33 40.90 31.57 — 1.98 2.20
Total current liabilities
8.38 45.78 48.08 27.00 22.15 50.56 36.58 2.36 12.04 11.34
Non-current Revenue (Deferred)
1.41 46.54 53.30 47.26 35.90 38.40 18.73 — — —
Non-current Liabilities (Other)
0.05 0.04 0.03 0.00 0.01 — — 9.07 13.59 19.80
Total non-current liabilities
1.46 46.58 53.33 62.74 51.84 52.24 30.98 9.07 13.59 20.23
Total liabilities
9.84 92.35 101.41 89.75 73.98 102.81 67.56 11.43 25.63 31.58
Additional Paid In Capital
129.35 136.48 189.93 227.47 242.67 307.00 318.53 1.82 156.33 163.34
Preferred Stock (Total)
— — — — — — — 70.60 — —
Common Stock (Net)
0.04 0.05 0.05 0.06 0.06 0.07 0.07 0.10 0.01 0.01
Retained Earnings
(102.66) (120.31) (147.07) (174.18) (211.41) (257.14) (290.42) (76.30) (93.73) (135.45)
Shareholders Equity (Other)
(1.50) (4.69) (2.98) (1.99) (0.29) 0.83 (0.25) 0.03 0.00 0.08
Common Equity (Total)
25.23 11.52 39.94 51.35 31.03 50.76 27.93 (74.48) 62.61 27.98
Shareholders Equity (Total)
25.23 11.52 39.94 51.35 31.03 50.76 27.93 (3.88) 62.61 27.98
Shareholders Equity and Liabilities (Total)
35.06 103.88 141.34 141.10 105.01 153.56 95.49 7.55 88.23 59.56
Shares (Common)
0.54 0.56 0.68 0.69 0.70 0.90 0.93 1.77 11.01 12.38
Shareholders Equity (Tangible)
25.23 11.52 39.94 51.35 31.03 50.76 27.93 (3.88) 62.61 27.98
Net Debt
(29.36) (72.63) (128.11) (104.15) (70.44) (117.76) (59.17) (7.35) (83.60) (57.98)
Total Debt
— — — 16.22 16.96 14.89 13.10 — — —

Fold the line items

In millions of $ except per-share values · columns are period end dates